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Background: Longitudinal data regarding the genotypes of Pseudomonas aeruginosa isolates after eradication treatment are limited. We followed
cystic fibrosis patients after a first ever isolation of P. aeruginosa and evaluated the P. aeruginosa-free time period after eradication therapy.
Methods: Between January 2003 and December 2008 respiratory samples were cultured prospectively from 41 patients with a first ever
P. aeruginosa isolate. Twenty five patients had at least one subsequent isolate. Treatment efficacy was assessed based on the time to a second
isolation and on comparison of the RAPD genotypes of the P. aeruginosa isolates.
Results: Eleven patients became chronically colonized during the study period. For ten of these the second isolate had the same genotype as the
first isolate. Moreover, these patients had a significantly shorter P. aeruginosa-free time interval between the first ever and the second isolate
compared to the 14 not chronically colonized patients (median 0 months versus 7.5 months, pb0.05).
Conclusion: Our results indicate that the presence of a genotypically identical subsequent P. aeruginosa isolate and/or a short P. aeruginosa-free
time interval after treatment are ominous signs and might be useful additional tools to predict impending chronic colonization. Current routine
bacteriological methods for the detection of P. aeruginosa may lack the sensitivity to discriminate between true eradication and low bacterial
persistence.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: P. aeruginosa; Eradication treatment efficacy; Genotyping1. Introduction
Pseudomonas aeruginosa is the major pulmonary pathogen
in patients with cystic fibrosis (CF) [1–3]. By adulthood, over
80% of the patients are chronically infected with this pathogen,
a condition which adversely affects lung function and survival
[4,5]. Chronic lung infection by P. aeruginosa increases
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doi:10.1016/j.jcf.2009.11.006chronically infected with P. aeruginosa, show a greater loss
of lung function [4,6] and a higher overall morbidity [7,8] in
comparison with non chronically infected CF patients. After a
first ever isolation of P. aeruginosa, patients may go through
different episodes of colonization, preceding chronic coloniza-
tion by months to years, eventually resulting in chronic
infection.
Early treatment of initial P. aeruginosa colonization can
postpone the onset of chronic colonization [9–11] and main-
tain or increase pulmonary function [12]. Genotyping of
P. aeruginosa isolates was previously applied in epidemiolo-
gical studies of P. aeruginosa in chronically colonized CF
patients [13–15], but longitudinal data on the genotype of
P. aeruginosa isolates after initial colonization and eradication
treatment are limited [16–18].d by Elsevier B.V. All rights reserved.
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first ever P. aeruginosa isolation and compared the genotypes of
P. aeruginosa isolates of subsequent positive cultures with that of
the first ever positive culture. The objectives of this study were to
assess the efficacy of eradication treatment by calculating the
P. aeruginosa-free period between the first ever and the second
P. aeruginosa isolation and by comparing the genotypes of the
initial and the subsequentP. aeruginosa isolates, both for patients
becoming chronically colonized and for patients remaining free of
chronic colonization.
2. Materials and methods
2.1. Patients and sampling
Between January 2003 and December 2008, sputum samples
or nasopharyngeal aspirates (NPA) were prospectively collected
and cultured from CF patients with a first ever P. aeruginosa
isolation attending the Cystic Fibrosis Center of the Ghent
University Hospital. Patients were seen every three months and
sputum or nasopharyngeal aspirate samples were cultured at
every control visit. Nasopharyngeal aspirates were collected in
case the patients could not expectorate sputum. After each
isolation of P. aeruginosa, a treatment with oral ciprofloxacin
(15 mg/kg bid) and inhaled tobramycin (80 mg bid) or colistin
(2.106 IU bid) was given for three months [19]. Treatment
failure was defined as a P. aeruginosa-positive culture at the end
of the eradication treatment period. In cases where a new
P. aeruginosa-positive culture was obtained after the first
successful eradication treatment period, new eradication treat-
ment(s) were initiated as long as the criteria for chronic colo-
nization were not fulfilled.
Definitions of colonization, chronic colonization, infection
and chronic infection are used according to the European
consensus criteria [20]. The European CF consensus group
defined lung colonization as: “Presence of P. aeruginosa in the
bronchial treewithout direct (inflammation, fever, etc.) or indirect
(specific antibody response) signs of infection and tissue
damage”, whereas chronic lung colonization was defined as
“Presence of P. aeruginosa in the bronchial tree for at least
6 months, based on at least three positive cultures with at least one
month intervals between them without direct (inflammation,
fever, etc.) or indirect (specific antibody response) signs of
infection and tissue damage”. Chronic infection is defined as
“Presence of P. aeruginosa in the bronchial tree for at least
6 months, based on at least three positive cultures with at least one
month intervals between them with direct (inflammation, fever,
etc.) or indirect (specific antibody response) signs of infection
and tissue damage”.
2.2. Culture and identification of the bacteria
Sputum samples, or nasopharyngeal aspirates–for patients not
producing sputum–were cultured for P. aeruginosa monthly
during the eradication treatment period, and every 3 months after
the eradication treatment period. Sputum samples were diluted
with Sputasol (Oxoid Ltd., Basingstoke, UK)(1:1, vol/vol) andafter 1 h of incubation at 37 °C, the samples were cultured onto
MacConkey Agar (Becton Dickinson, Erembodegem, Belgium).
After 2 days of incubation at 37 °C, lactose negative and oxidase
positive colonies were picked, at least four per sample and from
all of the different colony morphology types, subcultured on 5%
sheep blood agar (Becton Dickinson) and identified to species
level using tDNA-PCR [21,22].
2.3. DNA extraction of bacteria for PCR based amplification
DNAwas extracted from cultured bacteria by alkaline lysis. One
colony was suspended in 20 μl of lysis buffer (0.25% SDS, 0.05 N
NaCl and 95 ml sterile distilled water) and heated for 15 min at
95 °C.After a short spin, 180 μl of HPLC-waterwas added and this
mixture was centrifuged again for 5 min at 16,300×g to precipitate
bacterial debris. The supernatant was used as the DNA-extract in
the PCR based amplification assay.
2.4. Genotyping
All P. aeruginosa isolates were genotyped by randomly am-
plified polymorphic DNA analysis (RAPD) using Ready-to-Go
beads (Amersham Biosciences AB, Uppsala, Sweden) and primer
OPM1 (GTTGGTGGCT), as described previously [22]. The PCR
products were electrophoresed at 100 V on an agarose gel of 1.5%
(w/v) and visualized on a UV transilluminator after staining with
ethidiumbromide. Similarity between the obtained fingerprintswas
established by visual comparison of the RAPD patterns for each set
of isolates from the same patient on the same gel.
2.5. Statistical evaluation
Statistical significances of differences in P. aeruginosa-free
periods between groups were calculated with the non-parame-
trical Wilcoxon test. The significance of identical consecutive
P. aeruginosa isolates to predict chronic colonization was
calculated using the χ² test.
3. Results
Forty one CF patients, 21 males, with a median age of
4 years (range 6 months–30 years) at first P. aeruginosa
isolation, for whom P. aeruginosa was isolated for the first
time during the study period, were included (Table 1). Patient
38 died during the study period.
Patients were followed after the first eradication treatment
for a median period of 50 months (range 5–67 months).
In twenty out of the 41 patients P. aeruginosa was cultured
out of nasopharyngeal aspirates samples at the time of the first
isolation of P. aeruginosa. Two of these 20 patients became
able to expectorate sputum during the course of the study.
Initial eradication treatment failed in seven patients (Table 1,
patients 35–41), resulting in immediate chronic colonization.
Initial eradication treatment was successful in 34 patients (83%).
At present, 16 of these 34 patients (47%) (Table 1, patients 1–16)
remain free ofP. aeruginosa after the eradication treatment for the
Table 1
Genotypes of first ever and subsequent P. aeruginosa isolates of 41 newly colonized CF patients.
Patient
no.
Sputum/
NPA
Age at first
P. aeruginosa
isolation
(years)
Number of
P. aeruginosa
positive
episodes
Genotype(s)
of isolate(s) of
1st episode
Genotype(s)
of isolate(s) of
2nd episode
Genotype(s)
of isolate(s) of
3rd episode
Genotype(s)
of isolate(s) of
4th episode
Genotype(s)
of isolate(s) of
5th episode
Follow-up
period since first
P. aeruginosa
isolation
(months)
Time interval
between last
P. aeruginosa
isolation and end
of study period
(months)
1 SP 22 1 A 5 5
2 SP 9 1 A 5 5
3 NPA 4 1 A 6 6
4 SP 24 1 A 16 16
5 SP 11 1 A 29 29
6 SP 8 1 A 31 31
7 SP 10 1 A 36 36
8 NPA 4 1 A 37 37
9 NPA 3 1 A 38 38
10 NPA 3 1 A 40 40
11 NPA 2 1 A 41 41
12 NPA 28 1 A 51 51
13 NPA 5 1 A 53 53
14 SP 6 1 A 61 61
15 NPA 2 1 A+B 63 63
16 NPA 0.5 1 A 63 63
17 SP 4 2 A+B A+C (6) 9 3
18 SP 3 2 A B (15) 21 6
19 NPA-SP 5 2 A+B A (26) 37 12
20 SP 4 2 A B (9) 39 30
21 SP 4 2 A B (55) 61 3
22 NPA 2 2 A B (22) 61 36
23 NPA-SP 2 2 A A (4) 24 18
24 SP 19 3 A A (2) A (9) 33 18
25 NPA 3 3 A B (6) C (21) 37 6
26 SP 24 3 A B (3) C (39) 56 6
27 SP 2 3 A A (28) B (6) 57 18
28 NPA 1 4 A A (3) A(5) A (4) 30 6
29 NPA 1 5 A A (2) A(1) B(9) A (6) 64 11
30 SP 17 5 A B (22) A(9) B(7) B (1) 64 12
31 NPA 1 N5 A A (10) A A ND 47 0
32 NPA 4 N5 A A (33) A ND ND 50 0
33 NPA 6 N5 A A (2) A ND ND 51 0
34 NPA 1 N5 A A+B (4) A (3) A A 67 0
35 SP 4 N5 A A B B ND 61 0
36 SP 21 N5 A A A ND ND 26⁎ 0
37 SP 30 N5 A A A ND ND 40⁎ 0
38 SP 3 N5 A A A ND ND 24⁎⁎ 0
39 NPA 4 N5 A A A ND ND 35 0
40 SP 20 N5 A A A ND ND 24 0
41 SP 20 N5 A A A ND ND 18 0
ND: genotype not determined because the patient was already considered as chronically colonized.
‘A’, ‘B’, ‘C’: genotype numbering, whereby the codes A, B and C refer to the different P. aeruginosa genotypes observed for each patient, but the use of the same code
for isolates of different patients does not indicate similarity between isolates from different patients. When two genotypes are present, both are listed, e.g. ‘A+B’.
A/B or C (number): genotype (months after previous isolation of P. aeruginosa-counted from the end of the eradication treatment).
⁎Follow-up period till transplantation.
⁎⁎Follow-up period till death.
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of 39 months (range 5–63 months).
The remaining 18 of the 34 patients with initial successful
eradication treatment (53%) (Table 1, patients 17–34) re-
acquired P. aeruginosa after a median P. aeruginosa-free
period of 7.5 months (range 2–55 months), counting from the
end of the eradication treatment period. In the group of 18
patients with subsequent P. aeruginosa-positive episodes after
the first eradication treatment, seven patients experienced onesubsequent episode of P. aeruginosa isolation, four patients 2
subsequent episodes, one patient 3 subsequent episodes and two
patients 4 subsequent episodes. Another four patients (Table 1,
patients 31–34) became chronically colonized after a median
period of 7 months (range 2–33 months).
Relying on biochemical parameters (BSR, CRP, leucocytosis),
none of the chronically colonized patients was chronically infected.
For each positive P. aeruginosa episode of the patients, at
least four isolates, or more in case of more than four different
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isolates were genotypically identical, even in cases where
morphological differences among the picked colonies were
observed. Only for patients 15, 17, 19 and 34 could we establish
the simultaneous presence of more than one genotype at one or
two of the sampling times. Genotypic diversity among the
isolates of the different patients was large and no patients
carried isolates with genotypes observed in other patients.
In total there were 25 patients with at least a second
P. aeruginosa-positive period (Table 1, patients 17–41). Eleven
(Table 1, patients 31–41) of these became chronically colonized
and 10 of these chronically colonized patients had identical
genotypes for first and second isolates, whereas identical
genotypes of first and second isolates were observed for only 7
of the 14 non chronically colonized patients (Table 1, patients17–
31) (pb0.0001, χ²). In addition, for the 11 patients becoming
chronically colonized during the study period, a signifi-
cantly shorter time interval between the first ever and second
P. aeruginosa-positive culture was found compared to the non
chronically colonized group (median 0, IQR 0–3 months, range
0–33 months, versus 7.5, IQR 3–22 months, range 2–55 months
(pb0.05)). It should be noted that the one chronically colonized
patient (patient 35) with a different genotype for the second isolate
compared to that of the first isolate, had genotypes for the
subsequent third and fourth isolates identical to that of the second
isolate.
4. Discussion
We followed patients after eradication treatment for a first
ever P. aeruginosa isolate. Eradication treatment success was
evaluated by determining the P. aeruginosa-free period since
the end of the eradication treatment period, and by comparing
the genotype of the initial P. aeruginosa isolate with that of
subsequent isolates.
Several studies have reported positive effects of eradication
treatment for P. aeruginosa colonization episodes in CF
patients, such as postponing the onset of chronic colonization
[9–11] and the maintenance of or increase in pulmonary
function [12]. Only three studies assessed the eradication
treatment success after a first ever P. aeruginosa colonization
episode by studying the time to recurrence [16–18] and in two
of these studies [16,17] the P. aeruginosa isolates were
genotyped. Comparison of the different studies is difficult
because of different methodology, different treatment regimes
and different definitions of chronic colonization, P. aerugi-
nosa-free time period and treatment failure. Munck et al. [16]
followed 19 CF patients (age range 3 months–14 years
7 months) after a first ever isolation of P. aeruginosa.
Eradication treatment consisted of IV antibiotic therapy,
using a combination of a β-lactam antibiotic (ceftazidime or
imipenem) and tobramycin, during 18–21 days, followed by
nebulized colistin for at least 2 months. Eradication was
achieved in all patients, but within a median time of 8 months
(range 3–25 months) all patients had a second P. aeruginosa
colonization episode during the 3 year follow-up period.
Taccetti et al. [17] followed 58 CF patients after eradicationtreatment for a first ever P. aeruginosa isolate. The patients
received ciprofloxacin (30 mg/kg bid) and inhaled colistin
during 3 weeks and treatment was prolonged to 3 months when
cultures remained positive. Eradication, in this study defined as
three consecutive negative respiratory cultures and negative
serum P. aeruginosa-antibody titers within a 6 month period
after treatment was achieved in 47 (81%) of 58 patients. From
these, 24 patients (51%) were re-colonized after a median
P. aeruginosa-free period of 18 months (range 4–80 months),
but no data are available on duration of treatment nor on follow-
up time of the individual patients.
Recently, Hansen et al. [18] published the 15 years experience
(the “Copenhagen experience”) of eradication treatment for
P. aeruginosa infection with oral ciprofloxacin and inhaled colistin
in 146 patients. The median observation time was 7 years (range
0.1–14.9 years) and themedian time to recurrence ofP. aeruginosa
was 5 months (range 0.2–112.8 months) for the 3-week-treatment
group and 10.4 months (range 0–98.2 months) for the 3-month-
treatment group. Although not explicitly mentioned, all 99 patients
with a first ever P. aeruginosa isolate seem to be re-colonized
during the study period. Although Hansen et al. [18] did not
address chronic colonization, twelve percent of the patients
developed chronic infection after a median time of 3.7 years
(range 0.5–10.3 years) after the first ever P. aeruginosa isolation.
The group of patients developing chronic infection had a
significantly shorter P. aeruginosa-free interval between the first
ever and second isolate. Treatment failure after treatment for the
first ever isolate, i.e. immediate chronic colonization, was a risk
factor for later development of chronic infection (OR 5.8).
The median time to recurrence of P. aeruginosa for not
chronically colonized patients, established in this study, was
7.5 months versus 8 months [16] and 18 months [17] respec-
tively in the other two studies of not chronically colonized
patients.
P. aeruginosa was re-acquired in 53% of the patients with
initial treatment success in our study, in 51% of the patients in
the study of Tacetti et al. [17] and in 100% of the patients
included in the studies of Hansen et al. [18] and Munck et al.
[16].
Longitudinal data on genotypes of P. aeruginosa isolates of
non P. aeruginosa colonized CF patients are scarce. In the
study of Munck et al. [16], 14 patients were colonized by a
P. aeruginosa strain with a genotypic profile different from that
of the first isolate and the other 5 patients had subsequent
P. aeruginosa isolates with identical genotypes. No difference
between both groups in terms of mean interval between first and
second P. aeruginosa isolations were found. Taccetti et al. [17]
reported data on genotyping for 16 patients with at least one
subsequent P. aeruginosa isolate and found that acquisition of
P. aeruginosa isolates with a different genotype occurred in
73% of the 50 episodes. These data were not presented in
relation to subsequent chronic colonization status.
In accordance with the recent findings of Hansen et al. [18],
who reported a significantly shorter P. aeruginosa-free period
between the first ever and second positive culture in CF patients
becoming chronically ‘infected’, this study indicates that
patients becoming chronically ‘colonized’ have a significantly
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second isolation.
Therefore, monthly cultures after a first successful eradi-
cation treatment might advance detection of subsequent
P. aeruginosa colonization episodes, advance new eradication
treatments and probably postpone chronic colonization.
We found a high incidence of re-colonization by isolates
with the same genotype: 64% of the 25 patients with at least a
second isolate were found to carry the same P. aeruginosa
genotype, suggesting eradication failure, whereby the period of
P. aeruginosa-free samples might be explained by too low
sensitivity of the microbiology detection methods.
The detection of an identical genotype in subsequent
P. aeruginosa-positive isolates reveals important clinical issues
concerning the sensitivity of routine microbiological cultures and
the evaluation of therapeutical success of eradication treatment.
Studies on new microbiological detection techniques such as
specific PCR tests and efficacy studies on different eradication
treatment protocols are urgently warranted.
We evaluated whether differences in sensitivities of sampling
methods (culture on NPA versus sputum samples) could contribute
to failure in detection of P. aeruginosa. The number of patients
with at least one subsequent P. aeruginosa isolate (25 patients, 12
NPA samples) is too low to detect statistical differences in sensi-
tivities between cultures on NPA or sputum samples. Nevertheless,
6 of the 7 immediately chronically colonized patients (Table 1,
patients 35–41) were sputum producers whereas in all of the
patients becoming chronically colonized after the second or third
episode (Table 1, patients 31–34), cultures were done on NPA
samples. Low sensitivity of culture on NPA samples [23] could
have delayed the diagnosis of chronic colonization.
The recurrence of isolates with the same genotype could also
be explained by re-infection from the same environmental source.
However, in a previous study on home contamination with
P. aeruginosa in CF patients with a first ever P. aeruginosa
colonization episode, we found that the home environment of
newly infected CF patients is not heavily contaminated with
P. aeruginosa and that a P. aeruginosa isolate with an identical
genotype to that of the patient could be detected in only 9 out of
the 50 houses [24].
Based on our study results, we suggest that after a first ever
P. aeruginosa colonization episode the presence of a genotypi-
cally identical P. aeruginosa in a subsequent isolate and/or a
short P. aeruginosa-free interval after treatment are ominous
signs and may be useful additional tools to predict impending
chronic colonization. Current routine bacteriological methods
for the detection of P. aeruginosa may lack the sensitivity to
discriminate between true eradication and low bacterial
persistence.
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